The low prevalence of colonic serrated adenocarcinoma with high KRAS mutational status at Cipto Mangunkusumo Hospital, Indonesia

Nur Rahadiani, Diah R. Handjari, Marini Stephanie, Ening Krisnuhoni



Background: Serrated adenocarcinoma (SA), a subtype of colorectal carcinoma, and the KRAS mutation, a strong marker for the patient’s response to anti-epidermal growth factor receptor therapy, have a clinical importance because of its progressive nature and tendency for chemoresistance. The purposes of this study were to (1) determine the prevalence of SA, (2) evaluate the histomorphological characteristics of SA and classical adenocarcinoma based on its prognostic factors, (3) determine the prevalence of the KRAS mutation in SA cases, and (4) identify the main characteristics of SA cases and classical adenocarcinoma with a KRAS mutation.

Methods: This study was conducted by reviewing hematoxylin-eosin-stained slides of colorectal carcinoma (CRC) cases from January 2013 to July 2015 at the Department of Anatomical Pathology Cipto Mangunkusumo General Hospital. The final diagnosis of SA was based on the Tuppurainen et al criteria and the KRAS mutation was evaluated using real-time polymerase chain reaction.

Results: Among the 117 adenocarcinoma cases, there were 41 unequivocal SA, 11 equivocal SA, and 65 classical adenocarcinoma. The prevalence rates of unequivocal and equivocal SA among all CRC cases were 7.7% and 2.1%, respectively. There were 11 (28.2%) cases of wild-type KRAS and 28 (71.7%) cases of mutated KRAS among all unequivocal SA cases. Tumor budding (TB) was the predominant prognostic factor.

Conclusion: The prevalence of SA among all CRC cases was 7.7%. The KRAS mutation was found in almost three-quarters of all SA cases.


colon cancer, KRAS mutation, serrated adenocarcinoma

Full Text:



  1. Peto R, Kramer BS, Mel Greaves, Hausen H, Victoria CG, Blackburn E, et al. The global and regional burden of cancer. In: Stewart BW, Christopher P Wild, editors. World cancer report 2014. Lyon: IARC Press; 2014. p. 16.
  2. Hamilton SR, Bosman FT, Boffetta P, Ilyas M, Morreau H, Nakamura S-I, et al. Carcinoma of colon and rectum. In: Bosman F, Carneiro F, Hruban RH, Theise ND, editors. WHO Classification of tumours of the digestive system. 4th ed. Lyon: IARC Press; 2010. p. 131–46.
  3. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41.
  4. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Anatomi. Kanker di Indonesia tahun 2010: data histopatologik. Jakarta: Direktorat Jenderal Pelayanan Medik Departemen Kesehatan RI; 2010.
  5. Fleming M, Ravula S, Tatischev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3(3):153–73.
  6. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am J Pathol. 2001;158(2):527–35.
  7. Mäkinen MJ. Colorectal serrated adenocarcinoma. Histopathology. 2007;50(1):131–50.
  8. Tuppurainen K, Mäkinen JM, Junttila O, Liakka A, Kyllönen AP, Tuominen H, et al. Morphology and microsatellite instability in sporadic serrated and non-serrated colorectal cancer. J Pathol. 2005;207(3):285–94.
  9. Siddiqui AD, Piperdi B. KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol. 2010;17(4):1168–76.
  10. Bettington M, Walker N, Clouston A, Brown I, Leggett B, Whitehall V. The serrated pathway to colorectal carcinoma: current concepts and challenges. Histopathology. 2013;62(3):367–86.
  11. Lee CT, Huang YC, Hung LY, Chow NH, Su PF, Ho CL, et al. Serrated adenocarcinoma morphology in colorectal mucinous adenocarcinoma is associated with improved patient survival. Oncotarget. 2017;8(21):35165–75.
  12. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42(1):1–10.
  13. Jass JR, Smith M. Sialic acid and epithelial differentiation in colorectal polyps and cancer--a morphological, mucin and lectin histochemical study. Pathology. 1992:24(4):233–42.
  14. Kim KM, Lee EJ, Ha S, Kang SY, Jang KT, Park CK, et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol 2011;35(9):1274–86.
  15. Murcia O, Juárez M, Hernández-Illán E, Egoavil C, Giner-Calabuig M, Rodríguez-Soler M, et al. Serrated colorectal cancer: molecular classification, prognosis, and response to chemotherapy. World J Gastroenterol. 2016;22(13):3516–30.
  16. U.S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. AHRQ Publication 08-05124-EF-3. Rockville, USA; Agency for Healthcare Research and Quality: 2008.
  17. García-Solano J, Pérez-Guillermo M, Conesa-Zamora P, Acosa-Ortega J, Trujillo-Santos J, Cerezuela-Fuentes P, et al. Clinicopathologic study of 85 colorectal serrated adenocarcinomas: further insights into the full recognition of a new subsets of colorectal carcinoma. Hum Pathol. 2010;41(10):1359–68.
  18. Wang LM, Kevans D, Mulcahy H, O'Sullivan J, Fennelly D, Hylland J, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol. 2009;33(1):134–41.
  19. García-Solano J, Conesa-Zamora P, Trujillo-Santos J, Mäkinen MJ, Pérez-Guillermo M. Tumor budding and other prognostic pathological features at invasive margins in serrated colorectal adenocarcinoma: a comparative study with conventional carcinoma. Histopathology. 2011;59(6):1046–56.
  20. Sajanti SA, Väyrynen J, Sirniö P, Klinturp K, Mäkelä J, Tuomisto A, et al. Annexin A10 is a marker for the serrated pathway of colorectal carcinoma. Virchows Arch. 2015;466(1):5–12.

Copyright (c) 2018 Nur Rahadiani, Diah R. Handjari, Marini Stephanie, Ening Krisnuhoni

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles and issues in Medical Journal of Indonesia have unique DOI number registered in Crossref.
Unique Visitors